Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Exploring the full spectrum of macrophage activation

Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

EMT: 2016

Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492 · see citing works

Cancer immunotherapy comes of age

Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · see citing works

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,087 · see citing works

EMT in cancer

Brabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Epithelial Mesenchymal Transition in Tumor Metastasis

Mittal, V. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043854 · Cited by 1,528 · see citing works

Targeting the TGFβ signalling pathway in disease

Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · see citing works

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · see citing works

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059 · see citing works

Oncogenic roles of EMT-inducing transcription factors

Puisieux, A., Brabletz, T., & Caramel, J. (2014) · Nature Cell Biology · doi:10.1038/ncb2976 · Cited by 1,032 · see citing works

Targeting TGF-β Signaling in Cancer

Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · see citing works

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini, B. I., Powles, T. B., Atkins, M. B., Escudier, B. J., McDermott, D. F., Suárez, C., Sergio Bracarda, A., Stadler, W. M., Donskov, F. N., Lee, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 991 · see citing works

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y., Byers, L. A., Zhang, X., Yi, X., Dwyer, D. W., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 972 · see citing works

Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells

Kudo‐Saito, C., Shirako, H., Takeuchi, T., & Kawakami, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.023 · Cited by 872 · see citing works

EMT, cell plasticity and metastasis

Chaffer, C. L., Juan, B. P. S., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 847 · see citing works

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839 · see citing works

Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients

Tan, T. Z., Miow, Q. H., Miki, Y., Noda, T., Mori, S., Huang, R. Y., & Thiery, J. P. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404208 · Cited by 792 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

Tumor microenvironment: Sanctuary of the devil

Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 776 · see citing works

A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis

Su, S., Liu, Q., Chen, J., Chen, J., Chen, F., He, C., Huang, D., Wu, W., Lin, L., Huang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.021 · Cited by 775 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

Epithelial-to-mesenchymal transition in cancer: complexity and opportunities

Zhang, Y., & Weinberg, R. A. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0656-6 · Cited by 660 · see citing works

Inflammation and EMT: an alliance towards organ fibrosis and cancer progression

López-Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 655 · see citing works

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis

Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609 · see citing works

Resistance to PD1/PDL1 checkpoint inhibition

O’Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 574 · see citing works

Stromal biology and therapy in pancreatic cancer: a changing paradigm

Neeße, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 562 · see citing works

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536 · see citing works

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 535 · see citing works

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Mak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez‐Canales, J., Wistuba, I. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 526 · see citing works

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

Macrophage polarity in cancer: A review

Najafi, M., Goradel, N. H., Farhood, B., Salehi, E., Nashtaei, M. S., Khanlarkhani, N., Khezri, Z., Majidpoor, J., Abouzaripour, M., Habibi, M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27646 · Cited by 491 · see citing works

Epithelial–mesenchymal transition (EMT) and metastasis: yes, no, maybe?

Diepenbruck, M., & Christofori, G. (2016) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2016.06.002 · Cited by 478 · see citing works

Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial–mesenchymal transition in hepatocellular carcinoma

Fan, Q., Jing, Y., Yu, G., Kou, X., Ye, F., Gao, L., Li, R., Zhao, Q., Yang, Y., Lu, Z., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.008 · Cited by 459 · see citing works

Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

Lou, Y., Diao, L., Parra, E. R., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 439 · see citing works

TGF-β signalling and its role in cancer progression and metastasis

Drabsch, Y., & ten Dijke, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9375-7 · Cited by 430 · see citing works

New insights into the role of <scp>EMT</scp> in tumor immune escape

Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414 · see citing works

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · see citing works

Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas

Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395 · see citing works

Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade

Ouzounova, M., Lee, E., Piranlioglu, R., Andaloussi, A. E., Kolhe, R. B., Demirci, M. F., Marasco, D., Asm, I., Chadli, A., Hassan, K. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14979 · Cited by 371 · see citing works

Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor

Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W. C., Kato, M., Prévost‐Blondel, A., Thiery, J. P., & Abastado, J. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001162 · Cited by 369 · see citing works

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356 · see citing works

Tumor promoting role of anti-tumor macrophages in tumor microenvironment

Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., & Baral, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.005 · Cited by 334 · see citing works

IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation

Li, Y., Wang, L., Pappan, L. K., Galliher-Beckley, A. J., & Shi, J. N. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-87 · Cited by 319 · see citing works

Macrophage functions in lean and obese adipose tissue

Thomas, D. D., & Apovian, C. M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.005 · Cited by 318 · see citing works

Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis

Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., de Crémoux, P., Bertheau, P., Badoual, C., Vielh, P. R., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 302 · see citing works

Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation

Taki, M., Abiko, K., Baba, T., Hamanishi, J., Yamaguchi, K. D., Murakami, R., Yamanoi, K., Horikawa, N., Hosoe, Y., Nakamura, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03966-7 · Cited by 296 · see citing works

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx183 · Cited by 295 · see citing works

EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET

Goossens, S., Vandamme, N., Vlierberghe, P. V., & Berx, G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.006 · Cited by 292 · see citing works

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells

Alsuliman, A., Çolak, D., Al‐Harazi, O., Fitwi, H., Tulbah, A. M., Al‐Tweigeri, T., Al-Alwan, M. M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 288 · see citing works

Hypoxia‐inducible factor‐1α/interleukin‐1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic‐inflammatory microenvironment

Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286 · see citing works

Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis

Ye, L., Chen, W., Bai, X., Xu, X., Zhang, Q., Xia, X., Sun, X., Li, G., Hu, Q., Fu, Q., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0977 · Cited by 276 · see citing works

The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253 · see citing works

Twist mediates suppression of inflammation by type I IFNs and Axl

Sharif, M. N., Šošić, D., Rothlin, C. V., Kelly, E., Lemke, G., Olson, E. N., & Ivashkiv, L. B. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051725 · Cited by 251 · see citing works

Checkpoint inhibitors in pancreatic cancer

Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 217 · see citing works

EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer

Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 209 · see citing works

M2 macrophages induce EMT through the TGF‐β/Smad2 signaling pathway

Zhu, L., Fu, X., Chen, X., Han, X., & Dong, P. (2017) · Cell Biology International · doi:10.1002/cbin.10788 · Cited by 206 · see citing works

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer‐Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 198 · see citing works

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · see citing works

Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis

Han, Y., Guo, W., Ren, T., Huang, Y., Wang, S., Liu, K., Zheng, B., Kang, Y., Zhang, H., & Liang, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.011 · Cited by 194 · see citing works

Tumor microenvironment: Interactions and therapy

Najafi, M., Goradel, N. H., Farhood, B., Salehi, E., Solhjoo, S., Toolee, H., Kharazinejad, E., & Mortezaee, K. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27425 · Cited by 185 · see citing works

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180 · see citing works

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174 · see citing works

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

Kim, S., Koh, J., Kim, M., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 166 · see citing works

IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization

Castaño, Z., Juan, B. P. S., Spiegel, A., Pant, A., DeCristo, M. J., Laszewski, T., Ubellacker, J. M., Janssen, S. R., Dongre, A., Reinhardt, F., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0173-5 · Cited by 166 · see citing works

Potential therapeutic targets of epithelial–mesenchymal transition in melanoma

Pearlman, R. L., de Oca, M. K. M., Pal, H. C., & Afaq, F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.029 · Cited by 165 · see citing works

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Herzberg, B., Campo, M. J., & Gainor, J. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0189 · Cited by 161 · see citing works

Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology

Zhan, H., Zhou, B., Cheng, Y., Xu, J., Wang, L., Zhang, G., & Hu, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.041 · Cited by 154 · see citing works

CCL2 is critical for immunosuppression to promote cancer metastasis

Kudo‐Saito, C., Shirako, H., Ohike, M., Tsukamoto, N., & Kawakami, Y. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9545-6 · Cited by 149 · see citing works

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 146 · see citing works

PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation

Qiu, X. Y., Hu, D. X., Chen, W., Chen, R. Q., Shi, Q., Li, C. Y., Li, Y. J., Xiong, X., Liu, D., Pan, F., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.002 · Cited by 144 · see citing works

Epithelial-mesenchymal transition leads to NK cell–mediated metastasis-specific immunosurveillance in lung cancer

Chockley, P. J., Chen, J., Chen, G., Beer, D. G., Standiford, T. J., & Keshamouni, V. G. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97611 · Cited by 143 · see citing works

TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells

Kawata, M., Koinuma, D., Ogami, T., Umezawa, K., Iwata, C., Watabe, T., & Miyazono, K. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr136 · Cited by 131 · see citing works

Milk Fat Globule EGF-8 Promotes Melanoma Progression through Coordinated Akt and Twist Signaling in the Tumor Microenvironment

Jinushi, M., Nakazaki, Y., Carrasco, D. R., Draganov, D., Souders, N. C., Johnson, M., Mihm, M. C., & Dranoff, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2147 · Cited by 125 · see citing works

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

Bouillez, A., Rajabi, H. N., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D. O., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120 · see citing works

Tumor-associated macrophage-derived cytokines enhance cancer stem-like characteristics through epithelial–mesenchymal transition

Chen, Y., Tan, W., & Wang, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168317 · Cited by 120 · see citing works

Programmed death‐ligand 1 expression at tumor invasive front is associated with epithelial‐mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma

Tsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., Oda, Y., Okano, S., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13237 · Cited by 119 · see citing works

Tumor-Associated Macrophages Derived TGF-β‒Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway

Cai, J., Xia, L., Li, J., Ni, S., Song, H., & Wu, X. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.613 · Cited by 117 · see citing works

PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma

Wang, Y., Wang, H., Zhao, Q., Xia, Y., Hu, X., & Guo, J. (2015) · Medical Oncology · doi:10.1007/s12032-015-0655-2 · Cited by 114 · see citing works

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

Sow, H. S., Ren, J., Camps, M. G. M., OSSENDORP, F. A., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 112 · see citing works

Epithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor

López‐Soto, A., Huergo-Zapico, L., Galván, J. A., Rodrigo, L., de Herreros, A. G., Astudillo, A., & Gonzalez, S. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202950 · Cited by 111 · see citing works

PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer

Chen, L., Xiong, Y., Li, J., Zheng, X. W., Zhou, Q., Turner, A., Wu, C., Lu, B., & Jiang, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480000 · Cited by 110 · see citing works

Cancer‐associated fibroblasts: Secretions, interactions, and therapy

Farhood, B., Najafi, M., & Mortezaee, K. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27703 · Cited by 109 · see citing works

Snail Up-regulates Proinflammatory Mediators and Inhibits Differentiation in Oral Keratinocytes

Lyons, J. G., Patel, V., Roue, N. C., Fok, S., Soon, L., Halliday, G. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/1078-0432.ccr-07-6735 · Cited by 103 · see citing works

COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells

Li, Z.-L., Ye, S., OuYang, L.-Y., Zhang, H., Chen, Y.-S., He, J., Chen, Q.-Y., Qian, C.-N., Zhang, X.-S., Cui, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1044712 · Cited by 98 · see citing works

Molecular Signatures of the Insulin-Like Growth Factor 1-Mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers

Cevenini, A., Orrù, S., Mancini, A., Alfieri, A., Buono, P., & Imperlini, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082411 · Cited by 96 · see citing works

B7-H1 Overexpression Regulates Epithelial–Mesenchymal Transition and Accelerates Carcinogenesis in Skin

Cao, Y., Zhang, L., Kamimura, Y., Ritprajak, P., Hashiguchi, M., Hirose, S., & Azuma, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2217 · Cited by 94 · see citing works

aPKC‐ι/P‐Sp1/Snail signaling induces epithelial–mesenchymal transition and immunosuppression in cholangiocarcinoma

Qian, Y., Yao, W., Yang, T., Yang, Y., Liu, Y., Shen, Q., Zhang, J., Qi, W., & Wang, J. (2017) · Hepatology · doi:10.1002/hep.29296 · Cited by 93 · see citing works

Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer

Ma, H., Liu, X.-Z., & Liang, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6619 · Cited by 92 · see citing works

Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck squamous cell carcinoma

Gao, L., Zhang, W., Zhong, W., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6657 · Cited by 91 · see citing works

WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial–Mesenchymal Transition

Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84 · see citing works

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

Lee, J. W., Zhang, Y. X., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J. Q., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 80 · see citing works

Pancreatic cancer stem cells: New insight into a stubborn disease

Zhan, H., Xu, J., Wu, D., Zhang, T., & Hu, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.004 · Cited by 79 · see citing works

Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity

Terry, S., Buart, S., Tan, T. Z., Gros, G., Noman, M. Z., Lorens, J. B., Mami‐Chouaib, F., Thiery, J. P., & Chouaı̈b, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1271858 · Cited by 78 · see citing works

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72 · see citing works

Anti‐PD‐L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma

Hirayama, Y., Gi, M., Yamano, S., Tachibana, H., Okuno, T., Tamada, S., Nakatani, T., & Wanibuchi, H. (2016) · Cancer Science · doi:10.1111/cas.13099 · Cited by 68 · see citing works

Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression

Akalay, I., Tan, T. Z., Kumar, P., et al. (2014) · Oncogene · doi:10.1038/onc.2014.151 · Cited by 65 · see citing works

A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer

Zhang, Q., Zhang, Y., Chen, Y., Qian, J., Zhang, X., & Yu, K. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2548 · Cited by 65 · see citing works

Macrophages and pancreatic ductal adenocarcinoma

Habtezion, A., Edderkaoui, M., & Pandol, S. J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.049 · Cited by 64 · see citing works

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer

Hamilton, D. H., Griner, L. A. M., Keller, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3059 · Cited by 60 · see citing works

PD-L1 Expression in Pancreatic Cancer

Zheng, L. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw304 · Cited by 60 · see citing works

Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling

Yang, Z., Xie, H., He, D., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9873 · Cited by 59 · see citing works

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

Liang, H., Liu, X., & Wang, M. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s178497 · Cited by 55 · see citing works

miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression

Miao, S., Mao, X., Zhao, S., Song, K., Xiang, C., Lv, Y., Jiang, H., Wang, L., Li, B., Yang, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19121 · Cited by 54 · see citing works

An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy

Yang, Y., Xu, W., Peng, D., Wang, H., Zhang, X., Wang, H., Xiao, F., Zhu, Y., Ji, Y., Gulukota, K., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.059 · Cited by 50 · see citing works

Natural Killer Cell–Derived Interferon‐Gamma Promotes Hepatocellular Carcinoma Through the Epithelial Cell Adhesion Molecule–Epithelial‐to‐Mesenchymal Transition Axis in Hepatitis B Virus Transgenic Mice

Chen, Y.-Y., Hao, X., Sun, R., Wei, H.-M., & Tian, Z. (2019) · Hepatology · doi:10.1002/hep.30317 · Cited by 49 · see citing works

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis

Grenga, I., Donahue, R. N., Gargulak, M. L., Lepone, L. M., Roselli, M., Bilušić, M., & Schlom, J. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.027 · Cited by 48 · see citing works

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma

Mlčochová, H., Macháčková, T., Rabien, A., et al. (2016) · Scientific Reports · doi:10.1038/srep31852 · Cited by 47 · see citing works

Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma

Ueno, T., Tsuchikawa, T., Hatanaka, K. C., Hatanaka, Y., Mitsuhashi, T., Nakanishi, Y., Noji, T., Nakamura, T., Okamura, K., Matsuno, Y., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25050 · Cited by 46 · see citing works

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer

Kumar, S., Davra, V., Obr, A. E., Geng, K., Wood, T. L., Lorenzo, M. S. D., & Birge, R. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1376155 · Cited by 44 · see citing works

Immunotherapy for pancreatic cancer: A long and hopeful journey

Xu, J., Wang, L., Cheng, Y., Zhang, G., Hu, S., Zhou, B., & Zhan, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.040 · Cited by 44 · see citing works

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

Suda, K., Rozeboom, L. M., Rivard, C. J., Yu, H., Ellison, K. E., Melnick, M. A., Hinz, T. K., Chan, D. C. F., Heasley, L. E., Politi, K. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.010 · Cited by 42 · see citing works

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression

Martínez‐Ciarpaglini, C., Oltra, S. S., Roselló, S., Roda, D., Mongort, C., Carrasco, F., González, J., Gómez, F. J. S., Tarazona, N., Huerta, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0124-5 · Cited by 38 · see citing works

Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition

Malek, R. A., Wang, H., Taparra, K., & Tran, P. T. (2017) · Cells Tissues Organs · doi:10.1159/000447238 · Cited by 37 · see citing works

MiR-200b attenuates IL-6 production through IKKβ and ZEB1 in human gingival fibroblasts

Matsui, S., Zhou, L., Nakayama, Y., Mezawa, M., Kato, A., Suzuki, N., Tanabe, N., Nakayama, T., Suzuki, Y., Kamio, N., et al. (2018) · Inflammation Research · doi:10.1007/s00011-018-1192-1 · Cited by 32 · see citing works

Importance of EMT Factor ZEB1 in cDC1 “MutuDC Line” Mediated Induction of Th1 Immune Response

Smita, S., Ahad, A., Ghosh, A., Biswas, V. K., Koga, M. M., Gupta, B., Acha‐Orbea, H., & Raghav, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02604 · Cited by 31 · see citing works

Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids

Lee, C. H. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.031 · Cited by 30 · see citing works

M7824: A promising new strategy to combat cancer immune evasion

Gatti-Mays, M. E., & Gulley, J. L. (2018) · Oncoscience · doi:10.18632/oncoscience.451 · Cited by 16 · see citing works

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack

Hamilton, D. H., McCampbell, K. K., & Palena, C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00143 · Cited by 10 · see citing works

Epithelial-mesenchymal transition-induced metastasis could be a bait for natural killer cells

Okita, R., Shimizu, K., & Nakata, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.19 · Cited by 5 · see citing works

Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer

Gainor, J. F. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.23 · Cited by 4 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance

Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H. (2020) · Cells · doi:10.3390/cells9020428 · Cited by 213 · see citing works

Signal transducer and activator of transcription 3 signaling in tumor immune evasion

Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67 · see citing works

Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy

Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21 · see citing works

Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumorsPreprint

Xu, H., Zhang, D., Zhao, C. H., Qin, L., Wei, R., Xi, L., & Li, F. (2022) · Research Square · doi:10.21203/rs.3.rs-1765232/v1

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies

Ilcus, C., Bagacean, C., Tempescul, A., Popescu, C., Pârvu, A. V., Cenariu, M., Bocșan, I. C., & Zdrenghea, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133385 · Cited by 42 · see citing works

Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies

Devereaux, K. A., Charu, V., Zhao, S., Charville, G. W., Bangs, C. D., van de Rijn, M., Cherry, A. M., & Natkunam, Y. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.034 · Cited by 6 · see citing works

Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors

Zhang, D., Xu, H., Zhao, C. H., Qin, L., Wei, R., Xi, L., & Li, F. (2023) · Human Immunology · doi:10.1016/j.humimm.2023.07.003 · Cited by 3 · see citing works